Apr 06,2022

Digital Therapeutics (DTx) Company Alex Therapeutics Raises $3.82 Million Funding

Stockholm-based Digital Therapeutics (DTx) company Alex Therapeutics announces it has secured a €3.5M funding round. The round was led by Hadean Ventures, a European specialist life science venture fund, with participation from Scale Capital and Bonit Capital, the Leksell (founder of medical device company Elekta) family office.

FUNDING FUNDING ROUND
View Analyst & Ambassador Comments
Go to original news
Apr 15,2022

Click Therapeutics Closes $15 Million Debt Financing from Silicon Valley Bank

Click Therapeutics, Inc. (“Click”), a leader in Digital Therapeutics™ as prescription medical treatments, today announced that it has secured a $15 million term loan from Silicon Valley Bank. Proceeds from the financing were used in part to retire Click’s existing term loan facility with K2 HealthVentures (K2HV). The remaining proceeds supplement the company’s current equity capital and will be used to advance Click’s prescription digital therapeutic pipeline.

FUNDING DEBT FINANCE
View Analyst & Ambassador Comments
Go to original news
Apr 26,2022

Biofourmis Receives Significant Growth Investment from General Atlantic to Surpass Unicorn Status

Biofourmis, a global leader in virtual care and digital medicine, today announced it has surpassed unicorn status with a $300 million Series D investment led by leading global growth equity firm General Atlantic. CVS Health (NYSE: CVS) and existing investors also participated in the round, which will help fuel the company’s next phase of growth. Biofourmis also announced that former Medtronic CEO and Chairperson at Intel, Dr. Omar Ishrak, will join the company’s Board of Directors as Chairman.

FUNDING SERIES D
View Analyst & Ambassador Comments
Go to original news
May 02,2022

Hello Heart Closes $70M Series D Funding Following Significant Increase in Employers Market Demand for Heart Health Solutions

Hello Heart, the only digital therapeutic that focuses on heart health, announced that it has raised $70 million in Series D financing to support significant growth in customer demand. Growth equity firm Stripes led the round.

FUNDING SERIES D
View Analyst & Ambassador Comments
Go to original news
May 05,2022

Digital therapeutics firm Sidekick lands $55M in Series B round

The firm plans to expand its chronic disease treatments across more therapeutic areas.

FUNDING SERIES B
View Analyst & Ambassador Comments
Go to original news
May 09,2022

Oncological digital therapeutics company Fosanis raises more than $10.5M

Fosanis announced today that it closed a Series A funding round worth more than $10.5 million (€10 million). Berlin, Germany-based Fosanis, which develops prescription digital therapeutics for all oncological indications, picked up investments from existing shareholder Ananada Impact Ventures, as well as new investors Debiopharm Innovation Fund, Ship2B Ventures and Equity Pitcher.

FUNDING SERIES A
View Analyst & Ambassador Comments
Go to original news
Jun 09,2022

DarioHealth Secures $50 Million Dollar Non-Dilutive Credit Facility with OrbiMed

DarioHealth Corp. (NASDAQ: DRIO), a leader in the global digital therapeutics (DTx) market, announced today it closed a senior secured term loan facility of up to $50 million with OrbiMed, a leading investor in the healthcare industry, providing non-dilutive capital to fund the continued development of its platform and the acceleration of its adoption in the multi-billion dollar global chronic disease management market.

FUNDING DEBT FINANCE
View Analyst & Ambassador Comments
Go to original news
Jun 17,2022

Swing Therapeutics scores $10.3M to support fibromyalgia DTx clinical trial

Digital therapeutics startup Swing Therapeutics wrapped up a $10.3 million Series A funding round led by Jazz Venture Partners. Other participants in the raise include Alumni Ventures, AME Cloud Ventures, Asahi Kasei Corporate Ventures, Gaingels, Kicker Ventures, Mana Ventures and Metrodora Ventures. Swing focuses on building and testing a digital therapeutic for fibromyalgia, which causes widespread musculoskeletal pain as well as fatigue, sleep, memory and mood problems and the company was founded in 2019 and launched with $9 million in seed funding.

FUNDING SERIES A
View Analyst & Ambassador Comments
Go to original news
Aug 10,2022

Biofourmis scores another $20M

AI-backed remote monitoring and digital therapeutics company Biofourmis added another $20 million to its Series D round, bringing its raise to $320 million. The extension funding comes from Intel Capital, the strategic investment division of chipmaker Intel. The company first announced its Series D in April, which boosted Biofourmis to unicorn status with a valuation of $1.3 billion.

FUNDING SERIES D
View Analyst & Ambassador Comments
Go to original news
Aug 19,2022

Japanese DTx app maker CureApp to receive $51M investment from Carlyle

Japanese medical technology firm CureApp is getting 7 billion yen ($51.4 million) in investment from global investment firm Carlyle as part of their strategic partnership. Carlyle is taking a minority stake in the company, which has so far raised 13.4 billion yen ($98 million) in capital funding.

FUNDING SERIES G
View Analyst & Ambassador Comments
Go to original news
Subscribe to FUNDING